Age-dependent chemotherapy response and vitamin D impact in paired patient-derived normal and tumor colorectal organoids
Authors:
- Asuncion Fernandez-BarralAFAsuncion Fernandez-Barral
- Antonio BarbachanoABAntonio Barbachano
- Silvia Rodriguez-MarreroSRSilvia Rodriguez-Marrero
- Luis del PesoLuis del Peso
- Alfonso Herreros-CabelloAHAlfonso Herreros-Cabello
- Nuria Rodriguez-SalasNRNuria Rodriguez-Salas
- Isabel PrietoIPIsabel Prieto
- Aurora BurgosABAurora Burgos
- Miguel Leon-ArellanoMLMiguel Leon-Arellano
- Damian Garcia-OlmoDamian Garcia-Olmo
- Tomas OllerosTOTomas Olleros
- Jose Manuel Gonzalez-SanchoJGJose Manuel Gonzalez-Sancho
Preprint
Abstract
Early-onset colorectal cancer (EO-CRC, <50 years) incidence is rising worldwide. Using paired patient-derived colorectal normal and tumor organoids, we demonstrate the therapeutic window of three standard chemotherapies. Normal organoids were more resistant than tumor organoids to 5-fluorouracil (5-FU) and oxaliplatin in both EO-CRC and late-onset CRC (LO-CRC) patients. However, for SN38, this therapeutic window was observed in LO-CRC but not in EO-CRC patients, revealing age-dependent differences in drug resistance. We also evaluated the effect of calcitriol, the active vitamin D metabolite with anti-CRC activity, on drug sensitivity. Calcitriol reduced the cytotoxicity of 5-FU and SN38 in normal organoids regardless of patient age, while it selectively decreased their cytotoxicity in EO-CRC but not in LO-CRC tumor organoids. This protective effect correlated with calcitriol antiproliferative action and transcriptional effects on drug-metabolism pathways. These findings identify clinically relevant age-dependent differences in chemotherapy response and support vitamin D-based strategies to design age-tailored precision treatments.Keywords
Funding Information
- MICIU/AEI/10.13039/501100011033 (PID2019-104867RB-I00)
- MICIU/AEI/10.13039/501100011033 (PID2022-136729OB-I00)